CME/CE Podcast: Using GLP-1 RAs to Reduce CV Risk in T2D

The NACE Clinical Highlights Show

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/using-glp-1-ras-to-reduce-cv-risk-in-t2d-9134

Summary
Type 2 diabetes (T2D) doubles a patient’s risk for atherosclerotic cardiovascular disease (ASCVD), which is the leading cause of morbidity and mortality in patients with T2D. The 2023 ADA guidelines now recommend consideration of GLP-1 RAs in patients with T2D and ASCVD or indicators of ASCVD risk, independently of A1C and metformin use. In this episode, Dr. Pam Taub reviews recent updates in the cardiovascular benefits and appropriate use of GLP-1 receptor agonists for managing patients with T2D.
Learning Objectives

• Incorporate early use of GLP-1 RA therapy in appropriate patients with T2D using a holistic approach, considering administration route and optimal dosing
• Overcome barriers to GLP-1 RA uptake and medication adherence in T2D through patient counseling to manage adverse effects

This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Association of Black Cardiologists, Inc. (ABC) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, contact NACE at [e-mail].
Summary of Individual Disclosures
Dr. Taub financial relationships:
Consultant: Amgen, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Esperion, Merck, Sanofi, Medtronic
Contracted Research: Amgen, Novartis
All her disclosures are related to cardiology
Dr. Morris financial relationships:
Consultant and advisor: Acorai, Regeneron, Merck
Speaker: Abbott, BI Lilly, Cytokinetics, Edwards Lifesciences, Ionis
Contracted Research: Boston Scientific, Cytokinetics, Ionis, Merck, Myokardia, Novartis
Stocks: Gilead Sciences
All her disclosures are related to heart failure.
All of the relevant financial relationships listed for these individuals have been mitigated.
Association of Black Cardiologists Planning Committee
Tierra Dillenburg has no relevant conflicts of interest with any ACCME-defined commercial interest.
Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosure of Commercial Support
This educational activity is supported by an independent educational grant from Novo Nordisk Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.